|
 |
|
|||||||
|
|||||||||
Papers In Press, published online ahead of print May 28, 2008
J. Lipid Res., doi:10.1194/jlr.M700470-JLR200
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Bioquímica, Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona 08025
Corresponding Author: jescola{at}santpau.cat
Liver X receptor (LXR) agonists increase both total fecal sterol excretion and macrophage-specific reverse cholesterol transport (RCT) in vivo. In this study, we assessed the effects of ABCG5/G8 deficiency as well as those on LXR agonist-induction of RCT from macrophages to feces in vivo. A [3H]cholesterol-labeled macrophage cell line was injected intraperitoneally into ABCG5/G8-deficient (G5/G8-/-), G5G8+/- and wild-type G5/G8+/+ mice. G5/G8-/-mice presented increased radiolabeled HDL-bound [3H]cholesterol 24 hours after the label injection. However, the magnitude of macrophage-derived [3H]cholesterol in liver and feces did not differ between groups. A separate experiment was conducted in G5G8+/+ and G5G8-/- mice treated with or without the LXR agonist T0901317. Treatment with T0901317 increased liver ABCG5/G8 expression, which was associated with a 2-fold increase in macrophage-derived [3H]cholesterol in feces of G5/G8+/+ mice. However, T0901317 treatment had no effect on fecal [3H]cholesterol excretion in G5G8-/- mice. Additionally, LXR activation stimulated the fecal excretion of labeled cholesterol after an intravenous injection of HDL-[3H]cholesteryl oleate in G5/G8+/+ mice, but failed to enhance fecal [3H]cholesterol in G5/G8-/- mice. Our data provide direct in vivo evidence of the crucial role of ABCG5 and G8 in LXR-mediated induction of macrophage-specific RCT.
Revised on April 30, 2008
Accepted on May 27, 2008
Liver X receptor-mediated activation of reverse cholesterol transport from macrophages to feces in vivo requires ATP-binding cassette (ABC) G5/G8
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Briand, M. Treguier, A. Andre, D. Grillot, M. Issandou, K. Ouguerram, and T. Sulpice Liver X receptor activation promotes macrophage-to-feces reverse cholesterol transport in a dyslipidemic hamster model J. Lipid Res., April 1, 2010; 51(4): 763 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhang, L. Yin, J. Anderson, H. Ma, F. J. Gonzalez, T. M. Willson, and P. A. Edwards Identification of Novel Pathways That Control Farnesoid X Receptor-mediated Hypocholesterolemia J. Biol. Chem., January 29, 2010; 285(5): 3035 - 3043. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. T. Cook, Z. Duniec-Dmuchowski, T. A. Kocarek, M. Runge-Morris, and C. N. Falany 24-Hydroxycholesterol Sulfation by Human Cytosolic Sulfotransferases: Formation of Monosulfates and Disulfates, Molecular Modeling, Sulfatase Sensitivity, and Inhibition of Liver X Receptor Activation Drug Metab. Dispos., October 1, 2009; 37(10): 2069 - 2078. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Junyent, K. L. Tucker, C. E. Smith, A. Garcia-Rios, J. Mattei, C.-Q. Lai, L. D. Parnell, and J. M. Ordovas The effects of ABCG5/G8 polymorphisms on plasma HDL cholesterol concentrations depend on smoking habit in the Boston Puerto Rican Health Study J. Lipid Res., March 1, 2009; 50(3): 565 - 573. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |